| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
905.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.28 - $7.57 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 15.1 |
| Insider 6 Months : 16.5 |
| Insider 3/6 Months : 32 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
881,377 |
1,158,106 |
1,587,274 |
1,587,274 |
| Total Buy Value |
$3,403,196 |
$4,784,606 |
$6,777,784 |
$6,777,784 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
4 |
6 |
8 |
8 |
| Total Shares Sold |
166,809 |
329,176 |
776,921 |
2,283,574 |
| Total Sell Value |
$709,023 |
$1,586,998 |
$4,171,859 |
$15,418,498 |
| Total People Sold |
6 |
6 |
9 |
10 |
| Total Sell Transactions |
8 |
15 |
46 |
109 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raab Michael |
President & CEO |
• • – |
2025-05-02 |
4 |
AS |
$4.25 |
$177,168 |
D/D |
(41,666) |
1,594,754 |
|
-11% |
|
| Raab Michael |
President & CEO |
• • – |
2025-05-02 |
4 |
OE |
$0.99 |
$20,625 |
D/D |
20,833 |
1,636,420 |
|
- |
|
| Mott David M |
Director |
– • – |
2025-05-02 |
4 |
B |
$4.22 |
$1,610,936 |
D/D |
381,377 |
2,396,871 |
2.39 |
-11% |
|
| Parsey Merdad |
Director |
– • – |
2025-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
42,056 |
42,056 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2025-04-04 |
4 |
AS |
$4.59 |
$191,151 |
D/D |
(41,666) |
1,615,587 |
|
-19% |
|
| Raab Michael |
President & CEO |
• • – |
2025-04-04 |
4 |
OE |
$0.99 |
$20,625 |
D/D |
20,833 |
1,657,253 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2025-03-07 |
4 |
AS |
$5.36 |
$223,199 |
D/D |
(41,668) |
1,635,138 |
|
-30% |
|
| Raab Michael |
President & CEO |
• • – |
2025-03-07 |
4 |
OE |
$0.99 |
$20,626 |
D/D |
20,834 |
1,676,806 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
570,217 |
1,655,972 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
136,680 |
317,723 |
|
- |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
136,680 |
422,648 |
|
- |
|
| Kelliher Mike |
See Remarks |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
136,680 |
296,680 |
|
- |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
105,200 |
409,004 |
|
- |
|
| Foster Eric Duane |
Chief Commercial Officer |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
136,680 |
316,680 |
|
- |
|
| Mott David M |
Director |
– • – |
2025-02-24 |
4 |
B |
$5.00 |
$388,738 |
D/D |
77,729 |
2,015,494 |
2.39 |
-28% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2025-02-20 |
4 |
S |
$5.62 |
$27,783 |
D/D |
(4,941) |
303,804 |
|
35% |
|
| Raab Michael |
President & CEO |
• • – |
2025-02-20 |
4 |
S |
$5.62 |
$129,124 |
D/D |
(22,964) |
1,085,755 |
|
35% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2025-02-20 |
4 |
S |
$5.62 |
$29,077 |
D/D |
(5,171) |
285,968 |
|
35% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2025-02-20 |
4 |
S |
$5.62 |
$24,128 |
D/D |
(4,291) |
181,043 |
|
35% |
|
| Raab Michael |
President & CEO |
• • – |
2025-01-31 |
4 |
AS |
$5.36 |
$223,355 |
D/D |
(41,666) |
1,108,719 |
|
-31% |
|
| Raab Michael |
President & CEO |
• • – |
2025-01-31 |
4 |
OE |
$0.99 |
$20,625 |
D/D |
20,833 |
1,150,385 |
|
- |
|
| Mott David M |
Director |
– • – |
2025-01-21 |
4 |
B |
$4.99 |
$992,672 |
D/D |
199,000 |
1,937,765 |
2.39 |
-25% |
|
| Rodgers Richard J |
Director |
– • – |
2025-01-16 |
4 |
OE |
$0.55 |
$55,000 |
D/D |
100,000 |
350,524 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2025-01-07 |
4 |
AS |
$5.31 |
$221,309 |
D/D |
(41,666) |
1,129,552 |
|
-25% |
|
| Raab Michael |
President & CEO |
• • – |
2025-01-07 |
4 |
OE |
$0.99 |
$20,625 |
D/D |
20,833 |
1,171,218 |
|
- |
|
169 Records found
|
|
Page 1 of 7 |
|
|
0.02 (0.51%) 
